Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Total Voting Rights

1st Jul 2009 08:01

RNS Number : 8707U
Allergy Therapeutics PLC
01 July 2009
 



Wednesday 1 July 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Appointment of Directors, Directors Holdings and Total Voting Rights

AIM Rule Disclosure- Schedule 2(g)

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that further to the announcement made by the Company on 12 June 2009, Alejandro Esteban Weinstein Manieu (51) and Manuel Llobet (45) were today appointed as directors of the Company.

In accordance with Rule 17 of the AIM Rules, the following information can be disclosed regarding Alejandro Weinstein and Manuel Llobet:

Alejandro Weinstein

Current directorships and partnerships

Past directorships and partnerships within the last five years

Genomika Foundation

Laboratorios Recalcine S.A.

Biomedical Research Consortium

Manuel Llobet

Current directorships and partnerships

Past directorships and partnerships within the last five years

Drokasa Peru S.A.

Gynopharm S.A. (Costa Rica) 

Gynopharm S.A. (Colombia)

Laboratorios Elea México S.A. de C.V.

Servicios Elche S.A. de C.V.

Laboratorios Atlas

Gynopharm de Venezuela C.A.

Farmindustria S.A.

There is no further information to be disclosed under Schedule 2(g) of the AIM Rules for Companies.

Directors' holdings

After Admission, the interests of the Directors and the percentage of the Company's issued share capital which they represent are as follows:

Number of Ordinary Shares

% of Share Capital after Admission

Keith I Carter

3,192,669

1.21%

Ignace R Goethals

4,897,912

1.86%

Ian Postlethwaite

0

0.00%

Tom Holdich

0

0.00%

Christian Gratz

510,658

0.19%

Stephen R Smith

756,513

0.29%

Virinder Nohria

5,211

0.00%

Alejandro Weinstein*

0

0.00%

Manuel Llobet**

0

0.00%

*Alejandro Weinstein is a beneficiary of Azure Ventures Limited, which is interested in 104,166,666 shares, 39.46% of the Company

** Manuel Llobet is a beneficiary of Wild Indigo S.A, which is interested in 3,125,000 shares, 1.18% of the Company

Total Voting Rights Following Admission

The Company's issued voting share capital is 263,998,551 ordinary shares of 0.1p each.

For further information

Allergy Therapeutics

+44 (0) 1903 845 820

Keith Carter, Chief Executive

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAKXFEDSNEEE

Related Shares:

Allergy Thera.
FTSE 100 Latest
Value8,599.48
Change56.92